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A number of cardioprotective interventions have been identified throughout the years, and these include the 
use of natural antioxidants in sources like rooibos (Aspalathus linearis) tea. Recent studies have demonstrated 
that rooibos (either its isolated components or the crude rooibos extract/tea) confers cardioprotection in 
diabetic cardiomyopathy and myocardial ischaemic injury. In addition, a clinical study has shown that regular 
rooibos consumption reduces the risk for cardiovascular disease in adults. However, rooibos is currently 
not considered an official treatment against cardiac disease, mainly because the underlying mechanisms 
for rooibos-induced cardioprotection are not fully elucidated. Physiological actions of rooibos must be well 
investigated before rooibos can be used in a clinical setting as adjunct treatment for patients with heart 
disease. Thus, research to delineate the underlying mechanisms of rooibos-induced cardioprotection is key. 
In the light of the aforementioned, the available literature on rooibos-induced cardioprotection is reviewed 
here, highlighting the fact that rooibos preserves and maintains cardiac energy homeostasis. It is postulated 
that rooibos activates an AMPK-GLUT-4 glucose oxidation (cardiac energy-shortage sensing) pathway to 
shift cardiac energy usage, thereby conferring cardioprotection. 
Significance:
•	 It is hypothesised that rooibos may alter the way in which the human heart uses energy and oxygen, 
in order to protect the heart against disease. The heart’s mitochondria are responsible for the heart’s 
energy processes, and therefore are most likely involved in rooibos-induced cardioprotection. 
•	 Cardioprotection conferred by rooibos is likely via an AMPK-GLUT-4 glucose oxidation pathway. 
•	 The mechanism of cardioprotection is important for future studies investigating how rooibos alters 
cardiac mitochondria.
•	 The more information gathered about the underlying mechanisms of rooibos, the easier it will be to 
recommend rooibos as an official cardioprotective intervention in patients with heart disease. 
Introduction
Cardioprotection is the manipulation of cellular processes with various therapeutic interventions to protect the 
heart before, during or after disease.1-3 These interventions include pre- and post-conditioning4-6, remote ischaemic 
conditioning4-6, and intake of antioxidants like melatonin7,8 and rooibos (Aspalathus linearis)9,10. Rooibos is an endemic 
South African fynbos plant species that grows exclusively in the Cederberg mountain region.11,12 Research investigating 
rooibos mainly describes the multiple biological effects of the two forms of rooibos leaf extracts: unfermented green 
and fermented rooibos.13 Bioactive components within rooibos extracts/tea are categorised as polyphenols and 
flavonoids14,15 and are responsible for the anti-inflammatory, anti-cancer16,17 and antioxidant properties13,18, of rooibos. 
Considering that polyphenols and flavonoids have a well-documented role in cardioprotection19,20, rooibos extract is a 
possible candidate for cardioprotection21,22. 
Cumulative evidence suggests that either the individual rooibos components9,23,24 or the crude rooibos extract/
tea confers cardioprotection against heart disease in diabetes10 and heart attacks25. In one recent study, rooibos 
conferred cardioprotection in rats that were on antiretroviral therapy and displayed myocardial ischaemic damage.26 
However, in all these aforementioned studies, the mechanisms underpinning the rooibos-induced cardioprotection 
were not fully understood. Considering that rooibos is reported as a cardioprotective strategy for patients with heart 
disease21,22, the underlying mechanisms of rooibos-induced cardioprotection should be better understood. Without 
this understanding, in addition to a lack of evidence on the active ingredient(s) and safety/toxicity for patients taking 
heart disease medication27, rooibos may not pass clinical standards as a cardioprotective intervention for heart 
disease patients. If more information were gathered about the physiological mechanisms of rooibos, there would 
be a solid scientific foundation for the recommendation of rooibos as an effective cardioprotective intervention in 
patients with heart disease. 
Considering the variety of bioactive components present in rooibos tea, it is likely that more than one component of 
rooibos contributes to cardioprotection. Additionally, these different components may activate different, yet synergistic, 
molecular pathways to bring about cardioprotection. This likelihood complicates the understanding of the underlying 
mechanisms of rooibos-induced cardioprotection. However, over the years, multiple studies have highlighted isolated 
mechanistic aspects related to rooibos-induced cardioprotection. To this end, a review paper is necessary to provide 
a novel perspective on current evidence, and to highlight a possible underlying mechanism for rooibos-induced 
cardioprotection. This elucidation of possible mechanisms might be useful for the design of future studies. 
Overview of cardiac energy substrate utilisation in cardioprotection
Cardiac energy substrate utilisation plays a key role in cardiomyopathies28,29 and cardioprotection30,31. In diabetes32,33, 
high blood glucose (hyperglycaemia) as well as high glucose uptake without simultaneous glucose utilisation/oxidation, 
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induces toxic effects on the heart34,35. It induces this toxicity by activating 
programmed cell death (apoptosis of cardiomyocytes)36 and thereby 
contributes to diabetic cardiomyopathy37. In this case, a sensible approach 
is to increase glucose oxidation, a pathway that can reduce the amount 
of glucose entering cardiomyocytes.38 This approach limits cardiomyocyte 
apoptosis and confers cardioprotection.39,40 Against this background, several 
therapeutic interventions modulate cardiac energy substrate utilisation in 
favour of glucose oxidation39,40, in order to confer cardioprotection. 
Another dimension to the negative impact of hyperglycaemia on the 
heart, is that it increases the production of toxic molecules called reactive 
oxygen species41 that contribute to oxidative damage in the heart during 
hyperglycaemia. Therefore, in theory, a therapeutic intervention that 
can (1) increase myocardial glucose oxidation and (2) reduce reactive 
oxygen species, would accelerate glucose breakdown and thus limit the 
toxic effects of hyperglycaemia on the heart (Figure 1, green side). 
ATP, adenosine triphosphate 
Figure 1:  This figure demonstrates the role of glucose- and beta-oxidation 
in mitigating diabetic cardiomyopathy and myocardial ischaemic 
injury. In diabetic cardiomyopathy, hyperglycaemia induces 
toxic effects on the myocardium (heart muscle) and, therefore, 
increased uptake and breakdown of glucose alleviates the impact 
of hyperglycaemia. During myocardial ischaemia, increased 
myocardial glucose oxidation is a better fuel option, as it 
produces sufficient ATP with an oxygen sparing effect. Shifting 
of myocardial energy metabolism toward glucose oxidation, 
irrespective of whether diabetic cardiomyopathy or ischaemia-
reperfusion is present, promotes cardioprotection. 
In the case of a heart attack (myocardial ischaemia), oxygen availability 
to the myocardium is markedly reduced.2 The heart normally generates 
energy through both glucose oxidation and fatty acid oxidation, while the 
latter uses less oxygen for the production of a similar amount of energy 
(adenosine triphosphate, ATP).42 Thus, if fatty acid (beta) oxidation is 
elevated during a heart attack and not altered, the already limited oxygen will 
be used to produce ATP, which will produce more severe ischaemic effects 
on the heart.29,43 Therefore, increased glucose oxidation during myocardial 
ischaemia is considered a better pathway as it produces sufficient ATP 
with an oxygen sparing effect.29,43 In keeping with this logic, previous 
reports have demonstrated that in myocardial ischaemia, pharmacological 
modulation of cardiac energy metabolism (how the heart uses glucose or 
fatty acids as energy) confers cardioprotection mainly because it increases 
glucose oxidation.31,44,45 Furthermore, other reports have demonstrated 
that a shift in cardiac energy substrate utilisation toward glucose oxidation 
(irrespective of whether cardiomyopathy is from hyperglycaemia or 
ischaemia) contributes to cardioprotection43,46 (Figure 1, blue side). 
Evidence that rooibos shifts cardiac energy 
substrate utilisation
A number of studies have demonstrated a link between rooibos and 
changes in energy substrate utilisation in the liver47 and skeletal muscle48. 
A recent study showed that rooibos reduced hepatic insulin resistance 
by modulating adenosine 5′ monophosphate activated protein kinase 
(AMPK) pathways.49 One research group was able to demonstrate that 
rooibos increases liver activity of adenosine AMPK.48 Similarly, rooibos is 
able to increase AMPK activity, glucose oxidation48, mitochondrial activity 
and ATP production in muscle50. AMPK is also the main sensor for cardiac 
energy status51, and thus this effect of rooibos on AMPK was also recently 
demonstrated in the heart9,10,52. Taken together, these findings demonstrate 
the ability of rooibos to modulate cardiac energy substrate utilisation. 
Rooibos also preserves and maintains cardiomyocyte ATP production9 and 
improves cardiac functional recovery25 by enhancing glucose oxidation9. 
From these data, it can be inferred that rooibos alters AMPK activity to 
enhance myocardial glucose uptake via glucose transport-4 (GLUT-4)48 in 
order to promote myocardial glucose oxidation (Figure 2). 
AMPK, 5’ AMP-activated protein kinase; GLUT-4, glucose transporter-4; RB, rooibos; 
ATP, adenosine triphosphate; PDH, pyruvate dehydrogenase complex; G-6-PD, 
glucose six phosphate dehydrogenase 
Figure 2:  This figure demonstrates that, after oral consumption, rooibos 
is metabolised in the liver, and after metabolism, metabolites 
are circulated to the heart. Upon entering cardiomyocytes, 
rooibos metabolites may change cardiomyocyte energy status 
and increase AMPK activity and GLUT-4 mediated glucose 
uptake. Subsequently, glucose oxidation is increased and 
beta-oxidation reduced (Randle Cycle), and, because of the 
antioxidant properties of rooibos, oxidative stress is mitigated. 
In concert, these changes increase metabolic activity (through 
increased ATP production, less oxygen used, increased 
functional recovery) and ultimately contribute to rooibos-
induced cardioprotection. Therefore, this figure depicts the 
postulated hypothesis that rooibos confers cardioprotection via 
an AMPK-GLUT4 glucose oxidation pathway. 
As a consequence of the feedback inhibition of increased glucose oxidation 
on beta-oxidation (also referred to as the Randle relationship)37, rooibos 
may reduce fatty acid uptake/oxidation9. In concert, these processes allow 
the myocardium to have a reasonably high cardiac mitochondrial activity, 
and consume less oxygen in order to produce sufficient ATP production 
(Figure 2). Although not tested, this hypothesis could explain the enhanced 
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myocardial functional recovery after ischaemia-reperfusion25, and the 
preserved cardiomyocyte ATP production9 as previously reported. 
Therefore, in Figure 2, a hypothesis is depicted contending that rooibos 
may alter the overall cardiomyocyte energy status, and act via an AMPK-
GLUT-4 glucose oxidation pathway to confer cardioprotection. Future 
studies could investigate this hypothesis, and test whether rooibos 
extracts are able to activate this pathway to execute its favourable impact 
on cardiac energy substrate utilisation, and confer cardioprotection. 
Furthermore, considering that pyruvate dehydrogenase53,54 and glucose-
6-phosphate dehydrogenase55 are regulators of glucose oxidation, it 
should also be investigated whether rooibos modulates these enzymes 
in order to activate this AMPK-GLUT-4 glucose oxidation pathway. 
Merely enhancing myocardial glucose oxidation may not solely 
account for rooibos-induced cardioprotection – other factors, such as 
reduced apoptosis signalling9,10,23,25 mitochondrial connexin-4356 and 
cardiolipin57, G-protein-coupled receptor kinase-258 and the reduction 
of reactive oxygen species21,59 may also contribute. There is a need for 
therapeutic interventions that confer cardioprotection, particularly those 
that can be consumed through dietary intake of rooibos. However, the 
cardioprotective properties of rooibos are not well described and the 
exact underlying mechanisms remain to be delineated.60 Therefore, 
ongoing research is necessary to aid in the understanding of how 
rooibos confers cardioprotection and studies investigating the underlying 
mechanisms should be a priority. The identification of these underlying 
mechanisms would contribute to the body of knowledge on rooibos-
induced cardioprotection, and possibly facilitate the use of rooibos as an 
accepted cardioprotective intervention in the clinical setting. 
Conclusions
Studies on rooibos-induced cardioprotection, particularly those studies 
using models of diabetic cardiomyopathy and myocardial ischaemic 
injury, were reviewed. Based on the evidence presented and discussed 
in this review, it is hypothesised that rooibos may alter myocardial energy 
status, acting via an AMPK-GLUT-4 glucose oxidation pathway to confer 
cardioprotection. Future studies could further investigate this hypothesis 
and the activation of the proposed pathway in a suitable experimental 
model of cardiomyopathy. 
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